Data Insights

Sefaxersen sodium by F. Hoffmann-La Roche for Geographic Atrophy: Likelihood of Approval

Sefaxersen sodium is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Geographic Atrophy. According to...

Data Insights

Satralizumab by F. Hoffmann-La Roche for Myasthenia Gravis: Likelihood of Approval

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Myasthenia Gravis. According to GlobalData,...

Data Insights

Alectinib by F. Hoffmann-La Roche for Inflammatory Myofibroblastic Tumor (IMT): Likelihood of Approval

Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Inflammatory Myofibroblastic Tumor (IMT). According...

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Ureter Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Ureter Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Ureter Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Uterine Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Uterine Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Uterine Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Glioblastoma Multiforme (GBM): Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Glioblastoma Multiforme (GBM). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Glioblastoma Multiforme (GBM)

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Anal Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Anal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Anal Cancer

Data Insights

Tocilizumab by F. Hoffmann-La Roche for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Tocilizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Tocilizumab in Diffuse Large B-Cell Lymphoma

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Craniopharyngioma: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Craniopharyngioma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Craniopharyngioma

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Relapsed Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Relapsed Acute Myeloid Leukemia

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Refractory Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Refractory Acute Myeloid Leukemia

Data Insights

Astegolimab by F. Hoffmann-La Roche for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval

Astegolimab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD)....

Likelihood of Approval and Phase Transition Success Rate Model - Astegolimab in Chronic Obstructive Pulmonary Disease (COPD)

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Hepatocellular Carcinoma: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Hepatocellular Carcinoma

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

Satralizumab by F. Hoffmann-La Roche for Demyelinating Diseases: Likelihood of Approval

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Demyelinating Diseases. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Demyelinating Diseases

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Gastric Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Gastric Cancer

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Nephrotic Syndrome: Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Nephrotic Syndrome. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Nephrotic Syndrome

Data Insights

Rituximab by F. Hoffmann-La Roche for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Rituximab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Marginal Zone B-cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Marginal Zone B-cell Lymphoma

Data Insights

Tominersen by F. Hoffmann-La Roche for Huntington Disease: Likelihood of Approval

Tominersen is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Huntington Disease. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tominersen in Huntington Disease